DelveInsight’s ‘Chondrosarcoma Market Research, Epidemiology, and Market Forecast-2030’ report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology as well as the market trends of Chondrosarcoma in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The Chondrosarcoma market report provides analysis regarding current treatment practices, emerging drugs like Ivosidenib and other promising candidates like Trabectedin, Olutasidenib, INBRX-109 and LY3410738. Market share of the individual therapies, and historical, current and forecasted Chondrosarcoma market size from 2017 to 2030, segmented by seven major markets.
The report also covers current Chondrosarcoma treatment practice/algorithm, guidelines, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities. It assesses the underlying potential of the market.
Chondrosarcoma comprises a group of locally aggressive or malignant cartilaginous matrix-producing neoplasms with diverse morphological features and clinical behavior.
They predominantly arise in bones derived from endochondral ossification, the most common sarcoma of bone in patients above the age of 20 years. It predominantly affects individuals in the fourth to the sixth decades of life. The most commonly involved sites are the bones of the pelvis followed by the femur, humerus and ribs.
Chondrosarcoma occurrence steadily increases with age, with a peak incidence in the fifth to the seventh decade. Chondrosarcomas can be divided into different subtypes based on morphology, molecular alterations, whether they arise de novo (primary) or from benign precursor lesions (secondary) and by their location within the bone [central (in the medulla) or peripheral (at the surface).
Chondrosarcoma is one of the main types of bone sarcoma that shows a considerable deficiency in response to chemotherapy and radiotherapy. While surgery remains a mainstay of treatment, chemo-and radiotherapy is used in this tumor, high rate of death, especially among children and adolescents, are reported. Due to high resistance to current conventional therapies in chondrosarcoma, there is an urgent requirement to recognize factors causing resistance and discover new strategies for optimal treatment